Therawis technology for use of exosome purification

Interest in exosome research has increased dramatically in recent years due to their unique functions as intercellular messengers, abilities to alter recipient cell bioactivities, as well as in disease diagnostics. Despite significant efforts made in this relatively new field of research, progress has been held back by challenges such as inefficient separation methods, difficulties in characterization, and lack of specific biomarkers. Current applied methods for exosome purification are ultracentrifugation, precipitation with PEG, immunocapture with antibodies against CD9, CD63, CD81, TSG, Rab5 and others, microfluidic isolation or filtration. All these methods do not isolate all exosomes mainly subpopulations or even destroy the microvesicles during purification. For example, exosome quantity and integrity are dependent not only on the blood drawing method but also on storage conditions. As depicted in the Figure below exosomes captured with Rab5 and ExoMag demonstrates that EDTA plasma results in the highest yield. Any storage condition gives lower yields in comparison to fresh samples.

Legend: Serum and plasma obtained from one healthy volunteer with different anticoagulants results in different yields (left). Yield is also dependent on storage conditions (right). CD 41 serves as control to confirm that exosomes are not derived from platelets.

Using our IP-secured methodology to detect and analyze single EVs, we found that our novel immunocapturing method is superior to other commercially available kits; ExoMag is up to 16-fold more efficient to isolate exosomes.


ExoMag is a novel and proprietary method to identify and to isolate exosomes as cell-derived micro-carriers from blood – superior to currently available methods. This new method facilitates the combination with any microbead or magnetic bead separation technology. High-level molecular resolution allows for categorization of exosomes as diagnostic entity.